The results from this study, coupled with similar findings that have been reported in ALK rearrangement-positive NSCLC, suggest that EGFR pathway activation may be a common mechanism of resistance to ROS1 inhibition. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.